Fluoguide: CEO Morten Albrechtsen presents at Redeye Investor Forum Göteborg – September 16th | Redeye (video presentation - 18 min. 10 sec):
"FluoGuide proceeds to seventh dose level (36 mg) with FG001 in the ongoing clinical phase I/II trial following continued improvement of tumor illumination with increasing doses"
"FluoGuide is pleased to announce that FG001 was well tolerated, and light was detected in all patients in the sixth cohort (24 mg), administered in the morning before surgery. The data from the sixth dose (24 mg) showed a continued improvement and clear illumination of the tumors in all three patients. The dose escalation committee has therefore recommended to initiate the seventh dose level (36 mg) in the ongoing clinical phase I/II trial"
"Regarding the illumination, the protocol is designed to continue dose escalation as long as illuminations improve"
"As this has continuously been observed including with the latest dose of 24 mg, the dose escalation will continue to the next dose level of 36 mg."
CEO (Morten Albrechtsen):
• "Also, with the latest dose of 24 mg FG001 we observed a further improvement in tumor illumination."
• "Based on this, we therefore continue to the next dose level of 36 mg in order to establish the optimal dose to be used in the second part of the ongoing trial as well as in the upcoming pivotal trials. Only by a thorough dose escalation and study of the optimal dose, we can be sure to fully unfold the potential of FG001 as a tool to improve cancer surgery”.
FluoGuide A/S ("FluoGuide" or the “Company”) is pleased to announce the first publication of preclinical data where the Company’s compound FG001 is used as a photothermal therapy agent for treatment of cancer. The new feature of FG001 complements the surgical targeting and opens new opportunities for the realization of clinical and commercial potential of the Company’s uPAR-targeting technology platform.
"The data now published is highly encouraging and supports the potential of FG001 in maximizing the outcome of surgery. I am personally excited over the expansion of our uPAR technology platform into photothermal therapy. Together with the additional cancer indications, this has the potential of helping many more cancer patients in the future.” says Andreas Kjaer, founder and CSO of FluoGuide A/S"